14971: 4.4; IEC 62304: 5.1.1; MDR: 23.1
- Risk acceptability criteria defined and justified - ISO
14971: 4.4; IEC 62304: 5.1.2; MDR: 1, 4
- Risk Management for AI ISO 24971-2 and other
relevant standards identifying risk to SaMD
- Review of regulatory databases for similar / existing
devices for risks.
16.2. I s the Risk Management Risk Management ISO 14971: 4.2 Top Management shall
Policy impacted? define and document a policy for establishing the criteria
for risk acceptability. See also ISO/TR 24971 for
guidance on defining a risk policy.
16.3. I ntended use and Safety Is the intended Use Impacted with respect to risk and
Characteristics defined? safety characteristics?
- Intended use documented and aligned - ISO 14971:
5.4; IEC 62304: 5.1.1; MDR: 1, 23.4
- Safety-related characteristics identified - ISO 14971:
5.4; IEC 62304: 5.2.2; MDR: 4
- Software safety classification performed - IEC 62304:
4.3; MDR: 6
16.4. H azard Identification & Have you performed a Hazard identification assessment
Risk Analysis and documented risk analysis? If not provide adequate
rationale.
- Hazards identified (device, software, data, AI-specific)
- ISO 14971: 5.5; IEC 62304: 5.2.1; MDR: 1, 4
- Hazardous situations described - ISO 14971: 5.5; IEC
62304: 5.2.2; MDR: 4
- Harms defined and clinically validated — ISO 14971:
5.5; MDR: 1, 8
© N. St John Lynch, DkIT 2025-2026 Confidential Page 29 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
- Software-specific hazards included — ISO 14971: 5.5;
IEC 62304: 5.2.2; MDR: 17
16.5. H ave you estimated the Ensure data is available to support risk evaluation or
risks and evaluated impact adequate rationale is provided.
on existing or new risks
(including estimating - Probability and severity estimated — ISO 14971:
probability and severity 5.5.2; IEC 62304: 5.4.1; MDR: 4
and acceptability?) - Risk acceptability evaluated — ISO 14971: 6; IEC
62304: 5.4.2; MDR: 4
- AI-specific risks evaluated (bias, drift, explainability) -
ISO 14971: 6; MDR: 1, 5, 17
16.6. H ave risk control - Risk control options identified — ISO 14971: 7.1; IEC
measures of existing risk 62304: 5.5.1; MDR: 4, 23.3
been impacted or - Controls implemented — ISO 14971: 7.2; IEC 62304:
potentially impacted by 5.5.2; MDR: 23.3
this change? - Verification of risk controls performed — ISO 14971:
7.3; IEC 62304: 5.6.1; MDR: 5
- Traceability from hazard → control → verification —
ISO 14971: 4.5; IEC 62304: 5.1.5; MDR: 23.1
16.7. A re new risk control - Risk control options identified — ISO 14971: 7.1; IEC
measures required for this 62304: 5.5.1; MDR: 4, 23.3
change? - Controls implemented — ISO 14971: 7.2; IEC 62304:
5.5.2; MDR: 23.3
- Verification of risk controls performed — ISO 14971:
7.3; IEC 62304: 5.6.1; MDR: 5
- Traceability from hazard → control → verification —
ISO 14971: 4.5; IEC 62304: 5.1.5; MDR: 23.1
16.8. H ave you assessed the - Residual risk estimated and evaluated — ISO 14971:
Residual Risk of existing 8; IEC 62304: 5.7.1; MDR: 4
risks impacted and new - Benefit-risk analysis performed — ISO 14971: 8; IEC
potential risks including 62304: 5.7.2; MDR: 1, 8
analysis of Benefit-Risk - Overall residual risk acceptable — ISO 14971: 9;
conclusions? MDR: 1
16.9. H ave you - Risk Management Report completed — ISO 14971: 9;
reviewed/updated the Risk IEC 62304: 5.8.1; MDR: 23.1
Management Report & - RMF includes all required elements — ISO 14971:
Documentation 4.5; MDR: 23.4
- Software documentation aligns with technical file —
IEC 62304: 5.1–5.8; MDR: 23.4
16.10. H ave you reviewed the - PMS data collected and analysed — ISO 14971: 10.2;
Production and Post- IEC 62304: 9.1–9.2; MDR: 1, 5, 23.4
Market Surveillance for
© N. St John Lynch, DkIT 2025-2026 Confidential Page 30 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
potential impact or - Software updates assessed for new risks — ISO 14971:
introduction of new risks? 10.3; IEC 62304: 9.3; MDR: 23.4
- CAPA integrated into risk management — ISO 14971:
10.4; IEC 62304: 9.3; MDR: 5
16.11. H ave you addressed AI - Bias risk identification & mitigation — ISO 14971:
Specific Risks including 5.5; MDR: 1, 5
but not limited to, Bias, - Drift monitoring plan — ISO 14971: 10; IEC 62304:
Drift, Autonomous 9; MDR: 5
Change, Monitoring - Explainability and transparency controls — ISO
Methods, Explainability & 14971: 7; MDR: 23.4
Transparency, Human in - Human-in-the-loop safety mechanisms — ISO 14971:
the loop safety 7; IEC 62304: 5.5; MDR: 5
mechanisms?
16.12. H ave you addressed ISO 62366-1, -2, -3
Usability risk?
- Is Usability Engineering File impacted?
- Are Usability studies required for this change?
- If not, provide rationale.
16.13. H ave you reviewed, UK Specific Requirements include: DCB0129, DCB0160
addressed clinical (NHS). https://digital.nhs.uk/services/clinical-safety/clinical-
procedure/pathway risks risk-management-standards
with clear communication
to stakeholders for If not impacted or relied upon for Software Risk
awareness and Engineering Rigor reduction, provide rationale.
responsibilities?
16.14. A re there new hazards / identify all documents with the risk management file with
hazardous situations ID & revisions that were reviewed, including identifying
identified? line items where applicable
16.15. W as a risk analysis provide evidence or reference documentation and
session/activity attendees with dates/signatures
documented within QMS
document control for this
change?
16.16. I s an update required to Is the benefit-risk conclusion/ratio impacted and if not,
the Benefit-risk provide rationale. If it is provided updated document.
conclusions?
16.17. H ave Top Management Top management shall review the suitability of the risk
been engaged at all the management process at planned intervals to ensure
appropriate steps with continuing effectiveness of the risk management process
evidence of same? and shall document any decisions and actions taken. This
may be part of the QMS review (e.g., at Management
Review or other appropriate interval/ QMS process). Key
Top Management responsibilities:
© N. St John Lynch, DkIT 2025-2026 Confidential Page 31 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
- Establish Risk Management Policy
- Establish Risk Management Plan
- Define roles and responsibilities
- Provide Adequate competent Resources and have
responsibilities defined in SOPs/Job Specifications
for risk management specifically
- Approve Risk Management Report
- Evaluate Overall Residual Risks
- Perform Risk Review for Risk Process Suitability
- Maintain Risk Management Process
These align with ISO 14971:2019 clauses 4.1, 4.2, 4.4,
4.5, and 9, and are critical for demonstrating management
commitment, oversight, and lifecycle integration
17. Software Risk Management (PD IEC TR 80002-1) ☐ N/A
17.0. Is there an impact to Software Risk Management or other software-specific aspects,
not already considered? If appropriate, check N/A and leave remaining questions in
this section blank. Provide rationale: Click or tap here to enter text.
17.1. N Are there software risks that Indicate whether software risk management is
are defined outside of ISO separately defined. Yes, No. If no, provide
14971? rationale. Software risk management is
required as part of IEC 62304 that meet the
requirements of ISO 14971. PD IEC/TR
80002-1:2009 provides guidance on the
application of ISO 14971 to medical device
software. Evidence: Sub-systems shall be
defined under procedures, plans, etc. Note:
Additional tools for software risk analysis may
be defined including Fault Tree Analysis for
Top-Down Risk Assessment method. Ref. ISO
31010 and IEC 61025 FTA, IEC 60812 FMEA.
17.2. Are there any new software If yes, where are these documented and have,
related adverse events, hazards, they been assessed for harm? Update the
hazardous situations, or harms Product Level Risk Management where a
related to this change? software risk can lead to potential harm of end
user(s).
Software should be performed on the whole
medical device (system), including software,
SOUP, AI and hardware and its environment.
Software risk management activities should
NOT be conducted in isolation from the
system. Some activities for risk management
© N. St John Lynch, DkIT 2025-2026 Confidential Page 32 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
may be best performed by software engineers
as an integral part of IEC 62304 Software
Development Lifecycle and can include
software risk identification. Isolation is not
accepted where software risks cannot be
managed in isolation from the overall medical
device risk management due to the
interdependence of hardware failures,
software failures and risk control measures.
Sub-systems shall be defined.
Evidence: provide risk analysis documented
review/outcomes.
17.3. Probability of occurrence Provide details of how probability of
methodology should be occurrence is captured or refer to SOP/Plan.
appropriate for software.
Figure 1 PD IEC TR 80002-1:2009 (current Jan 2026)
Note: software engineering rigor per IEC
62304 is defined based on severity.
17.4. Has the list of anomalies, IEC 62304 and ISO 14971 requires full risk
software bugs or defects been analysis and evaluation. However, software
reviewed for risk and escalated anomalies are difficult to evaluate for
to product risk management as probability contributing to hazardous
appropriate? situations (ref. PD IEC 80002-1), since
software does not fail randomly in us.
Therefore, the method for evaluating software
bugs not be defined under a software-specific
risk management process. Integration and
escalation points should be defined. Risks
arising from software anomalies most often
are evaluated based on severity of harm alone.
Where potential harm meets the definition of
ISO 14971, escalation to product risk analysis
is required.
© N. St John Lynch, DkIT 2025-2026 Confidential Page 33 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
17.5. SOUP Anomaly List for Risk If Software of Unknown Provenance (SOUP) is
Management used, active monitoring and evaluating
publicly available anomaly lists and
information about the SOUP field performance
should be planned. Where possible this should
be supported by contractual agreement with
the SOUP supplier at the time of SOUP
acquisition.
17.6. User Interface(s) and Integration Software Graphical / User Interfaces are a
in a Clinical Setting necessary aspect of a software system that is
required to be planned, implemented and
iteratively reviewed and assessed for risk,
including prior to planned or unplanned
changes. Usability engineering (ISO 62366-x)
should include software- and AI-related
components. The processes shall be defined in
the software development plan or relevant
plan(s).
Note: IEC 80001-1 should be considered for
IT networks in a clinical environment with
responsibilities delineated between
manufacturer and healthcare technician
responsible for integration into IT network in a
clinical setting.
17.7. Are software checklists or Example questions:
software safety aspects
adequately considered, including - can the safety-related software item gain
fault tolerance? access to its processor when needed?
- can the safety-related software item be
guaranteed enough processor time to
complete its task before an unsafe state
develops into an accident?
- can it be demonstrated that no other
software item can corrupt or otherwise
interfere with the safety-related software
item?
- are the development methods adequate to
make risks visible to the designer(s) and
risk assessor(s) e.g., state machines, UML.
- What aspects require fault tolerance
design, i.e., ensuring the safety-related
functions continue to operate in the
presence of component faults, including
software anomalies (e.g., by use of
redundancy or switch to safe mode).
© N. St John Lynch, DkIT 2025-2026 Confidential Page 34 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
18. AI Risk Management (ISO/DTS-24971-2 2025) ☐ N/A
18.0. Does the change impact AI related risk management or potential risk scenarios? If not
indicate N/A and leave remaining questions in this section blank. Provide rationale:
Click or tap here to enter text.
18.1. Apply ISO 14971 risk Apply ISO 14971 risk framework to assessment of
management to machine- AI-related risks, or provide rationale for equivalent
learning medical devices. method. Include ML-specific hazards, drift, bias,
data issues, interoperability, accessibility (ref. EU
Accessibility Act), etc.
18.2. Are additional resources Ensure ML-specific oversight and review. Provide
required? appropriate resources to perform risk activities
with ML knowledge and, assign competent
personnel. Ensure team has ML, data, clinical,
usability, cybersecurity expertise
18.3. Has risk policy/plan(s) been Ensure review and acceptability criterion is
reviewed/updated to take appropriate for AI devices, including those capable
account of AI/ML medical of autonomous change.
devices including risk
acceptability criterion?
18.4. Does the risk management file Risks should cover the full MLMD lifecycle. Include
require updating, including for ML behaviour, drift, bias, data chain failures, refer
consideration of AI risks to ISO/TR 24971 or other appropriate standards for
throughout the full lifecycle methods and techniques. Identify AI specific
(concept through hazards, ref. Annex B & C (ISO/DTS-24971-2
decommission)? 2025)
18.5. Are there controls in place that Provide details. Define triggers, data collection,
ensure adequate monitoring, frequency, etc.
retraining, update criteria,
rollback provisions?
18.6. Is traceability maintained for Include dataset provenance, model versions
all hazards, controls, testing
and information provided to
end-user(s).
18.7. Have the AI/ML-specific Document and/or update the Characteristics
characteristics affecting safety related to safety for AI related risks. Provide
been documented? reference to documentation. Include data quality,
autonomy, explainability, bias, etc.
18.8. Is the estimate of risk suitable Use severity only where the probability is unknown.
for AI/ML devices? Consider data representativeness, usability studies.
Include ML performance drift & subgroup
performance.
18.9. Are controls to hazards Test with synthetic data, demographic bias checks
adequately verified?
18.10. Evaluate residual risk incl. Are explainability tools verified/validated.
transparency & explainability Disclosure must include ML limitations. Include
© N. St John Lynch, DkIT 2025-2026 Confidential Page 35 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
performance claims and differences with adequate
transparency for user needs. Address transparency
as a risk, identifying the risk of too much/too little
transparency.
18.11. Evaluate residual risk vs Consider autonomy level, novelty, UI usability,
benefits representative population, accessibility, etc.
18.12. How are significant residual Significant risks must be communicated. Consider
risks communicated to each documenting disclaimer notices on reports, etc. to
user/stakeholder; update as ensure user(s) including patients understand AI is
appropriate. used in the device and to what extent.
18.13. Ensure product risk Document Risk Management Plan, Analyses,
management requirements are Evaluation, Reporting, Review, Characteristics
met unless process / procedure related to safety, Benefit-Risk, etc.
indicates otherwise.
18.14. Determine the monitoring Set monitoring frequency for performance & drift
schedule for AI devices detection and user acceptance on an ongoing basis.
(locked and unlocked, Define the duration of the monitoring (e.g.,
continual/continuous learning). continuous throughout the full lifecycle and
frequency). Locked algorithms are subject to
change though not at the same rate. A rationale
should be provided for frequency and monitoring
employed.
18.15. Identify if update is required to Assign responsibility for collecting and monitoring
performance logs, error logs, logs and results to maintain performance.
drift monitoring metrics, etc.
18.16. Review post-market data for Identify safety signals linked to ML behaviour.
feedback associated with this Ensure retraining schedule and model updates are
device/change. adequate with rollback as needed. Document
planned re-training schedule and method including
method used for model updates. Provide reference
to documents, such as maintenance plan or
equivalent. Ensure versioning & traceability is
maintained.
19. Clinical Risk Management (NHS Digital Health Guidance) ☐ N/A
19.0. Does the change impact Clinical Risk Management (NHS)? If not indicate N/A and
leave remaining questions in this section blank. Provide rationale where a change is
made to a UK product: Click or tap here to enter text.
19.1. Is an assessment of Clinical Yes, No. If no, provide rationale.
Risk Management: its
application in the manufacture
of Health IT Systems –
Implementation Guidance, ID:
NPFIT-FNT-TO-TOCLNSA-
© N. St John Lynch, DkIT 2025-2026 Confidential Page 36 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
1300.06 required for Refer to
placement of this http://digital.nhs.uk/isce/publication/dcb0129 for
device/health software on the recent / updated versions.
UK market?
19.2. Is a clinical safety case report Yes, No. If no, provide rationale.
required for full impact
assessment of this change?
20. Security Lifecycle (IEC-81001-5-1 2021) ☐ N/A
20.0. Does the change impact security? If not, indicate N/A and leave remaining questions in
this section blank. Provide rationale where a change is made without impact to
security: Click or tap here to enter text.
20.1. Is the established security Security policy, responsibilities, risk ownership
governance process adequate
to support this change with
roles and responsibilities
assigned?
20.2. Perform security risk analysis Identify threats, vulnerabilities, controls. Identify
including AI specific risk AI specific risks, including but not limited to:
impacting security and Model poisoning, adversarial attacks, data
protection. poisoning, drift and continuous- or continual-
learning risks, explainability failures, model-
update compromise or failure, inference pipeline
DoS, bias risks, model theft, data, theft and misuse,
synthetic data misuse.
20.3. Are the security requirements CIA (confidentiality, integrity, availability)
adequately defined and tested? requirements, regulatory considerations. State the
regulations that are necessary to comply with and
the methods required for testing or refer to
documented plans/protocols.
20.4. Develop/review secure system Ensure Threat modelling is performed and
architecture for additional processes and procedures are in place to mitigate
threats. vulnerabilities (e.g., privilege separation)
20.5. Are secure coding and Identify process/procedures for security code
development impacted by this review with static analysis.
change?
20.6. Are existing security controls What has been reviewed/tested to ensure controls
adequate and verified? Are are acceptable e.g., pen-testing, security test
new security controls evidence.
required?
20.7. Is the secure release process Reference the processes in place for secure release
appropriate? and configuration maintenance and approval.
© N. St John Lynch, DkIT 2025-2026 Confidential Page 37 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
20.8. Are updates and patches Security advisories, vulnerability management plan
required to support this
change?
20.9. Have credible field logs, Monitor field security reports, Incident response,
incident reports and supplier and monitoring logs. Review device reports and
anomaly or device security lots security specialists, NIST, OWASP, etc.
identified a risk that could
impact this change?
20.10. Ensure risks with potential Identify threats, vulnerabilities, controls with
harm are escalated or traceable potential for harm to end user and ensure ISO
to product level risk analysis. 14971 is met.
21. Software / AI BOM (Bill of Materials) ☐ N/A
21.0. Does the change impact BOM? If not, indicate N/A and leave remaining questions in
this section blank. Provide rationale where a change is made without impact to BOM:
Click or tap here to enter text.
21.1. Identify SBOM / AIBOM SBOM and AIBOMs are necessary for security but
document ID version(s) are also valuable tools for identifying and risk
assessing software and security related risks as well
as applying SOUP controls per IEC 62304 where
applicable.
21.2. Are new software/ AI ☐ Yes, provide reference: Click or tap here to enter text.
components required to be ☐ No If no, provide rationale Click or tap here to enter
added to S/AI BOM text.
22. Information Security, Cyber and Privacy Protection (IEC 27001) ☐ N/A
Note: IEC 27001 is a non-healthcare specific standard. Refer to applicable standards for your
organisation for compliance or use as guidance only. This standard is used for establishing,
implementing, maintaining and continually improving an information security management
system.
22.0. Has an ISMS – Information Clause 4 Context; where an ISMS system is
Security Management System established and is maintained, review ISMS policy
been defined and certified? and process documentation for impact from
changes specified. Ensure the scope of the ISMS is
adequately defined, including boundaries and
applicability.
If an ISMS per IEC 27001 is not required,
indicate section as N/A and move to next section
(subsequent questions in this section can remain
blank where N/A is indicated).
© N. St John Lynch, DkIT 2025-2026 Confidential Page 38 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
22.1. Is there an impact to the Clause 4 Context; understand the organisation
organisation and its context? and its context. Identify internal and external
issues. What are the interfaces and dependencies
between activities performed by the organisation
(e.g., cloud computing) and those performed by
other organisations? Evidence: provide a list of
issues and content analysis.
22.2. Is there an impact to the Clause 4 Context; understand the needs of
stakeholders or needs of interested parties by identifying stakeholders and
interested parties? their requirements. Evidence: provide
stakeholder requirements document(s).
22.3. Is there a need for leadership Clause 5.1 Leadership; is a demonstration of top
understanding/acknowledgement management commitment necessary for this
dependent on the criticality or change. If so, provide evidence: meeting minutes,
nature of the change? leadership policy, statements or other. Refer to
5.1 for full list of methods of demonstration of
leadership (i.e., policy, strategy, integration into
organisation’s processes, resources,
communication, targets/outcomes, effectiveness,
promote improvement, support management).
22.4. Is there an impact to the ISMS Clause 5.2 Policy; is there an impact to the ISMS
Policy? Policy or objectives; has the ISMS Policy been
adequately defined? Is it available and
communicated? Evidence: an approved ISMS
policy shall be provided.
22.5. Is there an impact to Roles and Clause 5.3; are the ISMS roles and
responsibilities? responsibilities assignments documented?
Evidence: role assignment matrix/ job
specifications, escalation and approval matrices;
report(s) on performance of ISMS provided to Top
Management.
22.6. Has a Risk Assessment for ISMS Clause 6.1 Planning and Risk; has a risk
been performed to prevent, assessment process been defined and does it
reduce undesired effects and require updating following this change? Apply
achieve continual improvement? the risk assessment process to identify new or
emerging risks and assess risk controls already
defined? Evidence: risk assessment
documents/report(s).
22.7. Are the risk acceptance criteria Clause 6.1.2 the IS risk assessment process must
adequate or impacted by this define a risk acceptance criterion for performing
change? IS risk assessments, for consistent, valid and
comparable results that is capable of identifying
IS risks against loss of confidentiality, integrity
and availability for information within the scope
of the ISMS. Risk owners will also be identified
© N. St John Lynch, DkIT 2025-2026 Confidential Page 39 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
and security risks are analysed and evaluated
with prioritisation for risk treatment.
22.8. Does the Risk Treatment Plan Clause 6.1.3 Risk Treatment: The Risk Treatment
(with adequate controls) require Process shall be planned and documented, with
updating to the current State of treatment options suitable to the risks identified;
the Art? suitable controls shall be implemented, e.g.
collection of threat intelligence, inventory of
assets and owners maintained, acceptable use and
procedures for handling assets, information
transfer rules, procedures or agreements, access
control and rights, monitoring supplier services
with agreements in place, control process for
acquisition, use and exit from cloud services,
incident planning, definition and communication
with roles and responsibilities, etc. Ref. Annex A
22.9. Are objectives set impacted by Clause 6.2 Objectives and Planning. Objectives
this change? for Information Security (IS) should be set at
relevant functions and levels. They should be
consistent with the IS policy, be measurable
(where practicable), be monitored, communicated,
updated as appropriate and be available as
documented information. Planning will include: what
will be done, what resources are required, who is
responsible, completion targets and results
evaluated. All changes shall be carried out in a
Planned Manner! Evidence: documented
objectives and plans to achieve same.
22.10. Are the resources for IS Clause 7: determine and provide resources
impacted or additional necessary for establishing, maintaining and
resources necessary? improving ISMS. Evidence: resource allocation
records, job specifications, etc.
22.11. Is there an impact to or on Clause 7.2 Competence: competence of person(s)
competency arising from this doing the work related to IS shall be controlled
change? and valid in terms of education, training or
experience. Actions is necessary to correct any
deficiencies (training, mentoring, re-assignment)
and evaluate effectiveness of actions with records
to demonstrate competency.
22.12. Is awareness training impacted or Clause 7.3 Awareness: person(s) doing the work
required? under IS shall be aware of policy, their
contribution to effectiveness of ISMS and
implications for failure to perform as per ISMS.
22.13. Is there a need for internal or Clause 7.4 Communication: a decision is
external communication for this necessary in terms of the internal / external
change? communication(s) including, what is to be
communicated, when, to whom and how.
© N. St John Lynch, DkIT 2025-2026 Confidential Page 40 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
22.14. Is there a need for creation or Clause 7.5 (7.5.1, -2, -3) Documented
change to documented Information. The organisation’s ISMS shall
information? maintain relevant documentation as appropriate
to their size, complexity and competency to ensure
compliance and effectiveness of ISMS. Document
Control procedures shall ensure maintenance is
adequate (identification, description, format,
suitable, adequate, available, protected, storage,
etc.)
22.15. Are the operational processes Clause 8.1 Operational Planning and Control:
impacted or additional planning processes shall have established criteria and
or controls necessary? implementing control of processes in accordance
with the criteria. Documented information shall
be available to the extent necessary to have
confidence that the processes have been carried
out as planned, including planned changes and
review of consequences of unintended changes
with mitigation for adverse effects.
22.16. Review and update as applicable Clause 8.2 IS Risk Assessment (on-going):
risk assessment at least for perform IS risk assessments at planned intervals
significant changes or at planned or when significant changes are proposed or
intervals and/or as defined per occur, taking account of the established criteria.
policy/procedure(s). Evidence: Documented results.
22.17. Review and update Risk Clause 8.3 IS Risk Treatment (ongoing):
treatment plans. Implement the risk treatment plan and retain
results.
22.18. Is there an impact to the Clause 9.1 Monitoring, measurement, analysis
monitoring, measurement, and evaluation (MMAE): the ISMS shall
analysis and evaluation necessary document what needs to be monitored and
to be performed as part of ISMS? measured, when and by whom, including security
processes and controls; methods for same and
ensure valid results (comparable and
reproducible is necessary for validity. Evidence:
results of MMAE.
22.19. Does the change impact the Clause 9.2 Internal Audit: perform internal audits
internal audit schedule or drive a at planned intervals to SOPs and IEC 27001 to
need for a change to the audit demonstrate compliance and effectiveness. The
activities? audit planning shall include frequency, methods,
responsibilities, requirements and reporting. The
importance of processes shall be considered as
well as the previous audit findings. Audit criteria
and scope shall be defined for each audit.
Auditors selected shall be objective and impartial
and reporting to relevant management. Evidence:
retain records.
22.20. Is there an impact to Management Clause 9.3 Management Review (MR) should be
Review? defined and performed at planned intervals to
ensure continuing suitability, adequacy and
effectiveness. See 9.3.2 and 9.3.3 for Review
Inputs and Results. These include changes in
external and internal issues relevant to ISMS,
change in needs and expectations of interested
parties under ISMS and more. Evidence:
management review meeting minutes and
report(s).
22.21. Is there an impact to continual Clause 10.1 Continual Improvement should be
improvement actions or documented with identification and
activities? improvement. Evidence: improvement records/logs
or results of review.
22.22. Is there a need to initiate a Clause 10.2 Nonconformity (NC) and CA.
nonconformity and corrective Nonconformity shall be documented with action
action (CA)? taken to control and correct, determine cause,
assess potential for similar issues, etc. CA will be
appropriate to the effects of NCs. Evidence: NC
and CA records.
22.23. Adequate Controls Annex A: Appropriate evidence of adequate
controls should be demonstrated throughout the
ISMS. Refer to full list under Annex A. These
include but are not limited to Access Controls,
Cryptography, Physical Security, Supplier
Relationships.
23. Usability Analysis (ISO 32366-1, ISO 32366-3) ☐ N/A
23.0. Does the change impact usability? If not, indicate N/A and leave remaining questions in
this section blank? Provide rationale: Click or tap here to enter text.
23.1. How has usability incorporated Include explainability, transparency,
AI-specific risks and interpretability, bias.
requirements?
23.2. Are usability studies required to Provide details.
support this change?
23.3. Are processes/procedures Provide details.
adequately defined for usability
to incorporate AI related medical
devices.
© N. St John Lynch, DkIT 2025-2026 Confidential Page 42 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
24. Safety & Performance and Deployment ☐ N/A
24.0. Does the change impact safety and performance? If not, indicate N/A and leave
remaining questions in this section blank? Provide rationale: Click or tap here to enter text.
24.1. What measures/ metrics Provide details. Provide rationale for the
are used to demonstrate appropriateness of use of the measures/metrics
performance? chosen.
24.2. What claims are Provide details. Reference any IFU and
communicated to users promotional material(s) including web-site with
about safety and version control.
performance?
24.3. How will this change be Provide details.
deployed to produce /
clinical use?
24.4. How will this change be Provide details.
communicated to users /
stakeholders?
25. Post-market Performance Evaluation (clinical) ☐ N/A
25.0. Does the change impact post-market performance? If not, indicate N/A and leave
remaining questions in this section blank? Provide rationale: Click or tap here to enter text.
25.1. Is there a change to post- Provide details.
market plan(s),
surveillance or monitoring
to support this change?
25.2. How is this change Provide details. How can this change be checked in
monitored in use? post-production phase for safety and effectiveness?
25.3. What level of human Provide details. Reference monitoring protocols,
oversight (human in the PMS plans, etc.
loop) is applied to this
device and/or change?
26. Pre-determined Change Control Plan ☐ N/A
26.0. Does the change impact PCCP? If not, indicate N/A and leave remaining questions in
this section blank? Provide rationale: Click or tap here to enter text.
26.1. Is there an Authorised Yes/No, if Yes, define in what markets and regulatory
PCCP in place? authorities have review/approved the PCCP.
© N. St John Lynch, DkIT 2025-2026 Confidential Page 43 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
Has this change been included in the scope of the
authorised PCC? If yes, provide location/specific
detail as to how it is included.
26.2. Will this change Yes/No. Provide details. Identify all documents
support/change a new or required for creation / update of PCCP for
an authorised PCCP regulatory approval.
necessary to be reviewed
by regulatory authority?
27. Post-market Software Monitoring, Logging and Reporting ☐ N/A
27.0. Does the change impact monitoring, logging, reporting? If not, indicate N/A and leave
remaining questions in this section blank? Provide rationale: Click or tap here to enter
text.
27.1. What level of access is Provide details. Reference, monitoring or
available to software maintenance and vulnerability plan(s).
developers/ engineers/
legal manufacturer for
monitoring, logging and
reporting?
27.2. How is the data reviewed, Provide details. Reference procedures or plan(s) as
reported? applicable.
27.3. Is the reporting, Provide details. Reference procedures or plan(s) as
communication strategy applicable.
adequate for the device
including this change to
the device?
28. EU AI Act Regulation 2024/1689 (as amended) ☐N/A
28.0. Indicate if the AI Act Regulatory Requirements for Medical Devices is required? If
not, check N/A and leave the remaining questions blank.
28.1. Identify the intended purpose Article 8 stipulates that high-risk AI systems under
of the AI device/components the AI Act 2024/1689 must be subject to AI Act
and identify if this is different rules and regulations. Under the proposed change
from the intended purpose dated 16 Dec 2025, we have adopted the refined
stated above for the product. changes assuming adoption in 2026, where they
remove duplication and negative impact from
overly burdensome regulatory frameworks,
innovation and cost. According to the proposed
changes, Chapter III, Section will be applicable to
High-Risk AI systems, such as regulated AIeMD.
They adopt horizontal requirements that reflect
© N. St John Lynch, DkIT 2025-2026 Confidential Page 44 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
those already set out in MDR/IVDR 2017/745 and
2017/746 regulations.
28.2. Article 9 – Risk Management Risk Management shall comply with the ISO 14971
product and AI requirements already set out in this
document. In additional fundamental rights are
also included and should be considered as part of
risk management ref. (Lynch et al. 2026).
28.3. Article 10 – Data and Data Data used shall meet quality criteria and shall be
Governance subject to data governance and management
practices. This is reflected in the sections above.
Examination of biases is highlighted in relation to
fundamental rights and must be examined.
Training, validation and test data sets shall be
relevant, sufficiently representative and to be best
extent possible, free of errors and complete in view
of the intended purpose. Data sets shall take into
account, geographical, contextual, behavioural, or
functional setting in relations to intended use.
28.4. Article 11 – Technical Technical documentation shall be drawn up and
documentation maintained up to date. A single set of technical
documents shall be drawn up under the
MDR/IVDR (not a separate set for AI regulatory
compliance).
28.5. Article 12 – Record keeping Recording of logging for post-market surveillance
shall be implemented. Logging capabilities should
provide the recording period of each use of the
system (start date, and time and end date and time
of each use), database against which input data
was checked by the system, input data for which the
search led to a match and identification of the
persons involved in the verification of the results.
28.6. Article 13 – Transparency and Transparency shall enable deployers to interpret
provision of information to systems output and use it appropriately. IFU shall
deployers contain at least the identity and contact details of
the prover or authorised representative, the
characteristics, capabilities and limitations of
performance, the intended purpose, level of
accuracy and metrics used for robustness and
cybersecurity (refer Article 15) against which the
system has been tested and validated and what can
be expected – known and foreseeable
circumstances that may impact accuracy,
robustness and cybersecurity as well as residual
risks, technical capabilities and characteristics to
explain the output.
28.7. Article 14 – Human oversight Ensure the system can be overseen by human-in the
loop in order to prevent or minimise risk to health,
© N. St John Lynch, DkIT 2025-2026 Confidential Page 45 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
safety or fundamental rights that may emerge. This
shall be commensurate with the risk, level of
autonomy and context. The persons performing
such oversight will be aware of the capacities,
limitations and potential to rely or over-rely on
output as well as provision of tools to support
interpretation of outputs correctly.
28.8. Article 15 – Accuracy, Achieve appropriate level of accuracy, robustness
robustness and cybersecurity and cybersecurity to perform consistently
throughout their lifecycle. Address technical
methods to measure same. Declare in IFU.
Technical and organisation measures for resilience
to failures and errors shall be taken. Robustness
can be achieved through redundancy solutions
(back-up, fail-safe plans kick in). Feedback loops
or appropriate measures are adopted for
continuous/continual learning system. Security
risks are mitigated as identified above. Security
shall address measures to prevent, detect, respond,
resolve and control attacks.
29. Sustainability ☐ N/A
29.0. Does the change impact the sustainability policy or requirements? If not, indicate N/A
and leave remaining questions in this section blank? Provide rationale: Click or tap here to
enter text.
29.1. Have requirements been Provide details. Reference procedures or plan(s) as
determined for sustainability applicable. Review the EU AI Act (2024), Ecodesign
objectives? for Sustainable products Regulation ESPR, 2024 and
the Corporate Sustainability Due Diligence
Directive, CSDDD, 2024. Identify guidance or
requirements published for energy-efficiency
standards and sustainable AI design that are
applicable to AI-enabled medical devices (AIeMD).
Identify policy or procedures for sustainability
incorporated by the organisation.
29.2. How does this change support Provide details. Reference procedures or plan(s) as
sustainability objectives? applicable.
30. Technical Documentation, DMR and DHR ☐ N/A
30.0. Does the change impact technical documentation? If not, indicate N/A and leave
remaining questions in this section blank? Provide rationale: Click or tap here to enter text.
© N. St John Lynch, DkIT 2025-2026 Confidential Page 46 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
30.1. Is the Device History Record Provide details
(DHR) impacted by this change?
30.2. Is the Device Master Record Provide details
(DHR) impacted by this change?
30.3. Are the Product History Records Provide details
or Templates impacted by this
change?
30.4. Is the Declaration of Conformity Provide details
impacted by this change?
30.5. Has the technical documentation Provide details
been updated with full traceability
to this change?
31. Checklist of Deliverables arising from this Change ☐ N/A
31.0. Is a checklist for deliverables required to support this change? If not, indicate N/A and
leave remaining questions in this section blank? Provide rationale: Click or tap here to enter
text.
Based on the review performed, identify the deliverables necessary to review/updates required
for completion prior to implementation of change described.
31.1. Risk Management File ☐ n/a Provide details
31.2. Dataset Inventory and Data ☐ n/a Provide details
Quality Report
31.3. AI Model Card and ☐ n/a Provide details
reproducibility package
31.4. Test Protocols and Reports ☐ n/a Provide details.
31.5. Maintenance Plan / ☐ n/a Provide details.
Vulnerability Management Plan
31.6. Cybersecurity risk assessment, ☐ n/a Provide details.
mitigation and response plan
31.7. Vulnerability Management Plan ☐ n/a Provide details.
31.8. Post-market surveillance and ☐ n/a Provide details.
monitoring Plan
31.9. User documentation, IFU, ☐ n/a Provide details.
training materials, labelling,
limitations and intended use
31.10. Clinical evidence ☐ n/a Provide details. Study protocols, results
and statistical analysis
31.11. PCCP documents ☐ n/a Provide details.
© N. St John Lynch, DkIT 2025-2026 Confidential Page 47 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
31.12. Other: Click or tap here to enter ☐ n/a Provide details.
text.
Add additional rows as required
32. Regulatory Approval and Conformity Assessment / Certification ☐ N/A
32.0. Is a regulatory review required to support this change? If not, indicate N/A and leave
remaining questions in this section blank? Provide rationale: Click or tap here to enter text.
32.1. Regulatory Assessment of ☐ Significant Change
Change for Significance/
reporting ☐ Non-Significant Change
☐ Note to File / QMS Change to be notified to
authorities at next Recertification/Surveillance Audit
Is this change deemed significant and if so, what
authorities require reporting prior to implementation
of the change, where PCCP does not already cover the
scope of this change?
Provide rationale: Click or tap here to enter text.
32.2. Is a new conformity Provide details.
assessment required by
regulatory body (FDA,
Notified Body, other)?
32.3. Has regulatory approval been ☐ Yes, via Authorised PCCP – change is included in
granted for this change scope.
☐ Yes, via Authorised PCCP – change not included in
scope – updated authorised PCCP required
☐ Yes, granted and attached as a significant change.
☐ Yes, pending approval; change to regulatory
approval is required prior to implementation.
☐ No, approval is not required – minor change only
with Note to file or equivalent as per Quality/AI
Management System
☐ Attach or reference file/location with approval:
© N. St John Lynch, DkIT 2025-2026 Confidential Page 48 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
32.4. Have minimum AI Yes, minimum thresholds maintained
performance thresholds been
reviewed and maintained as No, minimum thresholds are not maintained and
documented by regulatory communication is necessary to relevant stakeholders
authority?
Provide list of minimum thresholds reviewed and
maintained: e.g., Accuracy (mean, macro, etc.),
Sensitivity (recall), Specificity, F1, AUC, etc.
32.5. Are all relevant regulations and ☐ EU AI Act
standards addressed and ☐ MDR 2017/745
General Safety and ☐ IVDR 2017/746
Performance Requirements ☐ Accessibility
checklists (GSPR) or Essential ☐ Interoperability
Requirements (ER) or relevant ☐ Data Protection
compliance documents updated ☐ Security
accordingly?
☐ RED
Add others as appropriate to territory and device type
32.6. Is an update required to the Provide reference to DoC document(s) review/updated
Declaration of Conformity and provide rationale if update is not deemed
(DoC) for the AIeMD? necessary.
33. Change Approval to Implement ☐ N/A
33.0. Is approval required under this form? If not, indicate N/A and identify method for
approval of change. Click or tap here to enter text. This form can be used as a supplemental
checklist as part of an existing eQMS with change control, where approval is documented
within the eQMS itself.
Role Name Signature Date
Author(s) e-signature is equivalent
to wet (ink) signature
Regulatory Affairs e-signature is equivalent
to wet (ink) signature
Quality Assurance e-signature is equivalent
to wet (ink) signature
Clinical/Medical e-signature is equivalent
to wet (ink) signature
Software Lead e-signature is equivalent
to wet (ink) signature
AI Governance Officer e-signature is equivalent
to wet (ink) signature
Data Protection Officer e-signature is equivalent
to wet (ink) signature
© N. St John Lynch, DkIT 2025-2026 Confidential Page 49 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
Other Click or tap here to enter ☐ n/a Provide details.
text. to wet (ink) signature
Add rows as required
34. Implementation & Effectiveness Plan ☐ N/A
34.0. Is an effectiveness plan required? If not, indicate N/A and identify method for
effectiveness checking of changes. Click or tap here to enter text.
34.1. Define Implementation Plan define or reference relevant change plan/ quality plan
and Targets or AI / Software Development plan with a list of
tasks/activities required to complete this change
including identification of assigned owners and target
dates. A Gantt chart may support this deliverable.
34.2. Are any change management Provide details. For example, Process Assessment
maturity assessments used to Model (PAM) (e.g., ISO/IEC 30105-2:2024) or
support improved projects, Process Reference Models (e.g., MDevSPICE®) – e.g.,
project safety and PD performance evaluation of devices
performance? demonstrates high performance and safety profile as
documented within Management Review’s assessment
of internal audits, complaints, data analysis, etc.
34.3. Identify effectiveness planning Document or reference how the change will be
and method for tracking to assessed for effectiveness and accomplishment of
completion. suitable QMS/AI governance objectives and
procedures.
34.4. Target date for completion dd/mmm/yyyy
© N. St John Lynch, DkIT 2025-2026 Confidential Page 50 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
35. Appendix: Additional Guidance
Figure 2 Where does AI fit within SDLC? (St John Lynch et al. 2025)
© N. St John Lynch, DkIT 2025-2026 Confidential Page 51 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
Figure 3 Example of AI System Lifecycle with Test-Specific Processes
© N. St John Lynch, DkIT 2025-2026 Confidential Page 52 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
Figure 4 Example AI Model Risks and Test Treatment. Ref. Annex C, (ISO/IEC/DTS-42119-2 2025)
© N. St John Lynch, DkIT 2025-2026 Confidential Page 53 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
Figure 5 Overview of Test Documentation
© N. St John Lynch, DkIT 2025-2026 Confidential Page 54 of 55
AIeMD Change CR No.: 0001
Management Assessment Template No.: TMP-001
Revision 01
36. References
EN ISO/IEC-62304. (2015). Medical device software: software life-cycle processes. IEC, ed. , 30
November 2015, p.84.
IEC-81001-5-1. (2021). Health software and health IT systems safety, effectiveness and security. Part
5-1, Security. Activities in the product life cycle. IEC, 2021, pp.1–66.
ISO/DTS-24971-2. (2025). Medical devices-Guidance on the application of ISO 14971-Part 2: Machine
learning in artificial intelligence (draft) Technical Specification ISO/DTS 24971-2:2025. Available
from: www.iso.org.
ISO/IEC/DTS-42119-2. (2025). AI - Testing of AI Part 2: Overview of testing AI Systems. Available
from: www.iso.org.
Lynch, N.S.J., Loughran, R., McHugh, M. and McCaffrey, F. (2026). Trustworthy Artificial Intelligence
in Healthcare: A Proposed Framework. In: Yilmaz, M. et al., eds. Systems, Software and Services
Process Improvement. Cham: Springer Nature Switzerland, pp.69–90.
St John Lynch, N., McHugh, M., Loughran, R. 1, McCaffrey, F. 1 and Kowalski, D. 2. (2025). Evaluating
Pre-trained 3rd Party AI Models in Medical Device Software Development for Responsible and
Ethical Use. In: 33rd International Artificial Intelligence and Cognitive Science. Dublin.
Table of Figures
Figure 1 PD IEC TR 80002-1:2009 (current Jan 2026) ........................................................................... 33
Figure 2 Where does AI fit within SDLC? (St John Lynch et al. 2025) ................................................... 51
Figure 3 Example of AI System Lifecycle with Test-Specific Processes ................................................. 52
Figure 4 Example AI Model Risks and Test Treatment. Ref. Annex C, (ISO/IEC/DTS-42119-2 2025) ... 53
Figure 5 Overview of Test Documentation ........................................................................................... 54
© N. St John Lynch, DkIT 2025-2026 Confidential Page 55 of 55